Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., filed a Form 4 on September 23, 2026, disclosing an open-market purchase of common stock transacted on September 22, 2026.

Key Highlights

  • Reporting person: Robert J. Bitterman, identified as Chairman, President, and CEO, as well as a Director of Phio Pharmaceuticals Corp.
  • Transaction: Purchase (transaction code P) of 2,000 shares of Common Stock, $0.0001 par value, on September 22, 2026.
  • Price paid: $1.0289 per share, according to the filing.
  • Resulting ownership: 364,871 shares of common stock beneficially owned following the transaction, held directly.
  • Footnote: The post-transaction total includes shares of common stock underlying unvested restricted stock units, per the filing's explanation of responses.
  • Filing signed: By Lisa C. Carson as Attorney-in-fact on September 23, 2026.

Robert Bitterman's Share Purchase at Phio Pharmaceuticals

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Robert J. Bitterman, who serves as Chairman, President, and CEO of Phio Pharmaceuticals Corp. (NASDAQ:PHIO), acquired 2,000 shares of the company's Common Stock, $0.0001 par value, on September 22, 2026. The transaction code recorded is "P," indicating an open-market purchase. The price per share reported in the filing is $1.0289.

Following the reported transaction, Bitterman's total beneficial ownership stands at 364,871 shares, held directly. The filing includes a footnote clarifying that this figure encompasses shares of common stock underlying unvested restricted stock units. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed on September 23, 2026, and was signed by Lisa C. Carson acting as Attorney-in-fact for the reporting person. The filing covers a single reporting person and reflects no amendment to a prior filing.

What Was Disclosed

The filing discloses a purchase of 2,000 shares of Phio Pharmaceuticals common stock by Chairman, President, and CEO Robert J. Bitterman at $1.0289 per share on September 22, 2026, resulting in total beneficial ownership of 364,871 shares, including shares underlying unvested restricted stock units.